$1.09 Million is the total value of ABG Innovation Capital Partners III GP Ltd's 3 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CSTL | CASTLE BIOSCIENCES INC | $763,983 | -3.5% | 33,626 | 0.0% | 70.27% | +16.3% | |
| AADI BIOSCIENCES INC | $193,062 | -43.6% | 26,666 | 0.0% | 17.76% | -32.0% | ||
| SYBX | SYNLOGIC INC | $130,133 | -16.8% | 205,906 | 0.0% | 11.97% | +0.2% | |
| IDRA | Exit | IDERA PHARMACEUTICALS INC | $0 | – | -56,250 | -100.0% | -1.50% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Fan Yu #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SYNLOGIC INC | 12 | Q3 2023 | 33.8% |
| AADI BIOSCIENCES INC | 9 | Q3 2023 | 37.2% |
| IDERA PHARMACEUTICALS INC | 9 | Q4 2022 | 2.4% |
| GENOCEA BIOSCIENCES INC | 8 | Q3 2022 | 32.1% |
| NABRIVA THERAPEUTICS PLC | 7 | Q2 2022 | 2.3% |
| CASTLE BIOSCIENCES INC | 6 | Q3 2023 | 77.2% |
| PULMONX CORP | 5 | Q4 2021 | 33.9% |
| AERPIO PHARMACEUTICALS INC | 3 | Q2 2021 | 2.3% |
| ATEA PHARMACEUTICALS INC | 2 | Q2 2021 | 91.0% |
| ATEA PHARMACEUTICALS INC | 1 | Q1 2021 | 80.1% |
View ABG Innovation Capital Partners III GP Ltd's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View ABG Innovation Capital Partners III GP Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.